Homo sapiens · seed P29274 · 412 aa · family defined as ≥30% identity to that seed · compiled 07 October 2026
Open in CODSWALLOP UniProt P29274 RCSB by accession PDBe-KB AlphaFold DB InterPro CATH 3.40.30.10 CATH 1.20.1070.10 CATH 1.10.530.40 CATH 1.20.120.10 CATH 3.40.50.2000 SCOP 8091190 SCOP 8044359 SCOP 8091152 SCOP 8091160 SCOP 8091150 SCOP 8057879 SCOP 8033861 SCOP 8091146 SCOP 8091148 SCOP 8038006 SCOP 8044069 SCOP 8091158 SCOP 8091214 SCOP 8091154 RCSB 9P1T PDBe
CATH and SCOP identifiers come from the RCSB's own structure annotations, which the Domains panel already reads, so these are looked up rather than guessed at.
Every figure here is counted over the whole family rather than quoted from one entry.
9P1T, the structure every other member of this family is superposed onto. Rendered by the RCSB and embedded here: the live app shows an interactive viewport, which a document that fetches nothing cannot.
How many of this family's constructs contain each residue of the seed. A trough is a stretch nobody has put in a construct, which is a construct-design answer rather than a disorder one.
204 distinct constructs across 559 entries. 514 polymer entities differ from the UniProt canonical sequence in some way, 90 carry a recognised expression tag and 212 carry a fusion partner.
"Differs from canonical" is not the same as "engineered". The canonical sequence is the full gene product, so a secreted protein whose structures all start after its signal peptide counts every one of them as different: lysozyme's most-used construct, residues 19–147 on 1,239 entities, is simply the mature protein. Read the construct column below for what was actually done, rather than this count.
| Entities | Length | Best (Å) | Best entry | What was made |
|---|---|---|---|---|
| 88 | 433 | 1.84 | 7IO5 | fused to BRIL (internal); residues 1-328; 1 internal deletion; M1P, A54L, T88A +16 more |
| 81 | 460 | 2.50 | 9Q3L | 3C/PreScission site; G16R, E27Q, M96T +4 more |
| 19 | 433 | 1.70 | 5NM4 | fused to BRIL (internal); residues 1-328; 1 internal deletion; M1P, A54L, T88A +17 more |
| 16 | 447 | 1.80 | 4EIY | fused to BRIL (internal); residues 1-330; 2 internal deletions; M1P, A317H, G318H +7 more |
| 10 | 449 | 1.94 | 8RW0 | fused to BRIL (internal); residues 1-328; 1 internal deletion; M1P, A54L, T88A +16 more |
| 9 | 315 | 2.30 | 4AMJ | residues 31-373; 1 internal deletion; V31M, S32G, R68S +12 more |
| 8 | 434 | 1.87 | 5OLG | fused to BRIL (internal); residues 1-328; 1 internal deletion; M1P, A54L, T88A +17 more |
| 8 | 506 | 2.40 | 6PS2 | His6; M1L, C54T, C97A +2 more |
| 7 | 313 | 2.70 | 2VT4 | residues 31-373; 2 internal deletions; V31M, S32G, R68S +12 more |
| 6 | 465 | 3.00 | 7EJ8 | matches the canonical sequence |
| 6 | 469 | 2.79 | 4LDE | fused to T4 lysozyme (internal); residues 17-348; 1 internal deletion; 2-residue insertion after 26; S17D, H18Y, A19K +12 more |
| 6 | 500 | 2.40 | 2RH1 | fused to T4 lysozyme (internal); residues 1-365; 1 internal deletion; G16R, E27Q, N187E |
| 5 | 307 | 2.50 | 6H7N | residues 39-373; 1 internal deletion; Q39A, W40A, E41A +14 more |
| 5 | 329 | 3.27 | 3UZA | residues 1-329; A54L, T88A, R107A +16 more |
| 5 | 336 | 2.13 | 6TOS | residues 25-399; 2 internal deletions; P25A, D26A, Y27S +21 more |
| 5 | 368 | 2.30 | 6TQ4 | residues 25-399; 1 internal deletion; P25A, D26A, Y27S +21 more |
| 5 | 508 | 2.50 | 8DCS | FLAG+His5; fused to T4 lysozyme (internal); residues 1-368; 2 internal deletions; M1L, G2F, D3Q +4 more |
| 5 | 794 | 2.86 | 8YH0 | His8; fused to GFP; 3C/PreScission site; M1G |
| 4 | 325 | 2.60 | 2YDV | residues 1-325; L48A, A54L, T65A +10 more |
| 4 | 341 | 2.59 | 9M2O | matches the canonical sequence |
| 4 | 421 | 2.30 | 5ZKC | fused to BRIL (internal); 3C/PreScission site; 1 internal deletion; N2D, N3D, N6D +2 more |
| 4 | 490 | 2.80 | 3D4S | His6; M1L, R12G, C54T +4 more |
| 3 | 353 | 2.63 | 9EE8 | FLAG; TEV site; residues 1-330; 1 internal deletion; M1A, V229C, R291A +9 more |
| 3 | 395 | 3.16 | 7DH5 | residues 1-386; M1G, A380E, A381N +5 more |
| 3 | 455 | 2.17 | 6ZFZ | His10; M1A, R12G, C54T +5 more |
Showing the 25 most-used of 204.
Columns where the wild-type residue still dominates but a real minority carries something else, which is a different question from "what varies across species".
| Oligomeric state | Chains | Entries | Share |
|---|---|---|---|
| monomeric | 1 | 333 | 59.6% |
| tetrameric | 4 | 81 | 14.5% |
| pentameric | 5 | 75 | 13.4% |
| dimeric | 2 | 39 | 7.0% |
| trimeric | 3 | 23 | 4.1% |
| hexameric | 6 | 8 | 1.4% |
185 entries have the depositor's assembly corroborated by PISA, 340 carry the depositor's word alone and 34 were assigned by PISA where the depositor gave none. The middle figure is not a disagreement: PISA may have returned nothing or never run. 11 entries carry more than one assembly with different chain counts, so they have no single answer to quote: 2VT4, 2Y00, 2Y01, 2Y02, 2Y03, 2Y04, 4DAJ, 4U14, 4U15, 5DSG, 5UIG.
Every source's own domains on the seed axis, one row each. They are not merged: Pfam, CATH, SCOP and InterPro disagree about boundaries, and a merged track would state a consensus none of them gave.
| Domain | Source | Span (seed) | Chains |
|---|---|---|---|
| Glutaredoxin | CATH 3.40.30.10 | 18–124 | 6 |
| Rhodopsin 7-helix transmembrane proteins | CATH 1.20.1070.10 | 28–326 | 95 |
| 1.10.530.40 | CATH | 206–364 | 35 |
| Cytochrome c/b562 | CATH 1.20.120.10 | 222–332 | 11 |
| Glycogen Phosphorylase B; | CATH 3.40.50.2000 | 280–412 | 5 |
| G protein-coupled receptor-like | SCOP2B 8091190 | 13–412 | 186 |
| Thioredoxin-like | SCOP2B 8044359 | 18–123 | 6 |
| G protein-coupled receptor-like | SCOP2B 8091152 | 21–315 | 20 |
| G protein-coupled receptor-like | SCOP2B 8091160 | 54–249 | 9 |
| G protein-coupled receptor-like | SCOP2B 8091150 | 63–412 | 41 |
| Cytochromes | SCOP2B 8057879 | 219–319 | 150 |
| Lysozyme-like | SCOP2B 8033861 | 226–385 | 41 |
| Component | Class | Name | Entries | Best (Å) |
|---|---|---|---|---|
| CLR | lipid/detergent | Cholesterol | 214 | 1.70 |
| OLA | lipid/detergent | Oleic Acid | 201 | 1.70 |
| OLC | lipid/detergent | (2r)-2,3-Dihydroxypropyl (9z)-Octadec-9-Enoate | 186 | 1.72 |
| NA | cofactor | Sodium Ion | 179 | 1.70 |
| G1I | ligand | (5r,6r)-6-(Methylamino)-5,6,7,8-Tetrahydronaphthalene-1,2,5-Trio | 81 | 2.90 |
| TEP | ligand | Theophylline | 79 | 1.84 |
| PEG | cryoprotectant | Di(Hydroxyethyl)ether | 64 | 1.80 |
| GTP | cofactor | Guanosine-5'-Triphosphate | 40 | 2.90 |
| SO4 | ion | Sulfate Ion | 37 | 2.11 |
| ZMA | ligand | 4-{2-[(7-Amino-2-Furan-2-Yl[1,2,4]triazolo[1,5-A][1,3,5]triazin- | 34 | 1.70 |
| OLB | lipid/detergent | (2s)-2,3-Dihydroxypropyl (9z)-Octadec-9-Enoate | 28 | 1.72 |
| DMS | cryoprotectant | Dimethyl Sulfoxide | 23 | 1.84 |
| SOG | ligand | Octyl 1-Thio-Beta-D-Glucopyranoside | 18 | 2.11 |
| 2CV | lipid/detergent | Hega-10 | 16 | 2.30 |
| PLM | lipid/detergent | Palmitic Acid | 14 | 2.40 |
| PG4 | cryoprotectant | Tetraethylene Glycol | 13 | 2.11 |
| CAU | ligand | (2s)-1-(9h-Carbazol-4-Yloxy)-3-(Isopropylamino)propan-2-Ol | 12 | 2.40 |
| Y01 | lipid/detergent | Cholesterol Hemisuccinate | 12 | 2.50 |
| PGW | ligand | (1r)-2-{[(S)-{[(2s)-2,3-Dihydroxypropyl]oxy}(Hydroxy)phosphoryl] | 11 | 2.11 |
| ADN | cofactor | Adenosine | 10 | 2.63 |
Parsed from the free text 334 depositors typed into
_exptl_crystal_grow.pdbx_details, out of 339
entries that recorded anything at all.
Median pH 5.5
(range 4.2 to 9.0).
559 entries carry a wwPDB validation report: 340 clean, 193 worth a check and 26 with something to explain. Median clashscore 5.26, median RSRZ outliers 5.84%, median R-free minus R-work 0.036. 559 have released structure factors.
| Organism | Entries | Best (Å) | Ligand-bound | Seed covered |
|---|---|---|---|---|
| Homo sapiens | 473 | 1.70 | 452 | 82% |
| Meleagris gallopavo | 30 | 2.10 | 29 | 70% |
| Tequatrovirus T4 | 19 | 2.50 | 19 | 81% |
| Escherichia coli | 11 | 2.71 | 10 | 82% |
| Rattus norvegicus | 5 | 2.80 | 5 | 34% |
| Influenza A virus (A/Victoria/3/1975(H3N2)) | 5 | 2.86 | 5 | 79% |
| Canis lupus familiaris | 3 | 3.16 | 3 | 70% |
| Acetivibrio thermocellus ATCC 27405 | 3 | 3.21 | 3 | 24% |
| Mus musculus | 2 | 2.92 | 2 | 72% |
| Enterobacteria phage RB59 | 2 | 3.20 | 2 | 71% |
| Ixodes scapularis | 2 | 3.39 | 2 | 69% |
| Escherichia coli K-12 | 1 | 2.70 | 1 | 70% |
412 residues, numbered every ten. Every identity figure in this document is measured against this sequence.
active or binding site modified residue or glycosylation disulphide cysteine transmembrane or signal the 15 most-substituted positions
Sites are UniProt's curated features where the seed is a UniProt accession; the substituted positions are measured from this family's own alignment rather than annotated, and only the fifteen most substituted are marked: every position carrying a minority substitution would be most of the protein, because the family holds orthologues. A residue can carry more than one and is drawn with the first that applies, in the order of the key above.
One record per paper, not per entry.
| Year | Citation |
|---|---|
| 2026 | An integrated experimental and computational pipeline for crystallographic fragment screening of membrane protein in the lipid cubic phase. Commun Chem doi:10.1038/s42004-026-02059-7 |
| 2026 | Structural Mechanism of an Efficacy Photoswitch Targeting the beta 2 -adrenergic Receptor. Angew.Chem.Int.Ed.Engl. doi:10.1002/anie.202517995 |
| 2026 | A biased allosteric modulator is a molecular glue for beta 2 AR dimerization. Nature doi:10.1038/s41586-026-10892-y |
| 2026 | Discovery of MK-1088 as a Potent A 2A /A 2B Adenosine Receptor Dual-Antagonist for Cancer Immunotherapy. J.Med.Chem. doi:10.1021/acs.jmedchem.5c03405 |
| 2026 | Next-generation chemogenetic inhibition using a brain-permeant non-prescription agent. Signal Transduct Target Ther doi:10.1038/s41392-026-02865-4 |
| 2026 | Development of a random background to understand ligand optimization. Nature doi:10.1038/s41586-026-11013-5 |
| 2026 | Mechanistic Basis for 5-HT 2A R Over 5-HT 2B R Activation. Nat Commun doi:10.1038/s41467-026-77659-x |
| 2026 | A novel fusion tool to enable G protein-coupled receptor structure determination. Acta Crystallogr D Struct Biol doi:10.1107/S2059798326003785 |
| 2026 | A negative survival pressure selection system enables GPCR antagonist screening. Cell Discov doi:10.1038/s41421-026-00892-7 |
| 2026 | Structure-based design of subtype-selective psychedelic analogs. Nat Commun doi:10.1038/s41467-026-77658-y |
| 2026 | A GPCR-G protein-beta-arrestin megacomplex enabled by a versatile allosteric modulator. Cell doi:10.1016/j.cell.2025.12.023 |
| 2026 | Structural insights into the binding mode of the hypnotic drug vornorexant to orexin receptors. Acta Crystallogr.,Sect.F doi:10.1107/S2053230X26003432 |
| 2026 | Large Library Docking for Polypharmacology. J.Med.Chem. doi:10.1021/acs.jmedchem.5c03810 |
| 2026 | Rapid and Label-Free Structural Proteomics Using One-Step Swift Trypsin LiP-MS. Acs Omega doi:10.1021/acsomega.5c11109 |
| 2026 | Decoding ligand recognition and constitutive activation of histamine H3 and H4 receptors. Acta Pharmacol.Sin. doi:10.1038/s41401-025-01633-4 |
| 2026 | Cryo-EM structure of a single-chain beta 1-adrenoceptor - AmpC beta-lactamase fusion protein. J.Struct.Biol. doi:10.1016/j.jsb.2026.108349 |
| 2025 | Identification of nanomolar adenosine A 2A receptor ligands using reinforcement learning and structure-based drug design. Nat Commun doi:10.1038/s41467-025-60629-0 |
| 2025 | Cryo-EM reveals an extrahelical allosteric binding site at the M 5 mAChR. Nat Commun doi:10.1038/s41467-025-62212-z |
| 2025 | Advancing macromolecular structure determination with microsecond X-ray pulses at a 4th generation synchrotron. Commun Chem doi:10.1038/s42004-024-01404-y |
| 2025 | Structural insights into nonpeptide antagonist inhibition of somatostatin receptor subtype 5. Proc.Natl.Acad.Sci.USA doi:10.1073/pnas.2522515122 |
| 2025 | Structure and function of a near fully-activated intermediate GPCR-G alpha beta gamma complex. Nat Commun doi:10.1038/s41467-025-56434-4 |
| 2025 | Structural insights into ligand recognition and G protein preferences across histamine receptors. Commun Biol doi:10.1038/s42003-025-08363-7 |
| 2025 | Chemosensation of the pheromone spermine by the olfactory TAAR-like receptor TAAR348. Cell Discov doi:10.1038/s41421-025-00839-4 |
| 2025 | Structure and dynamics determine G protein coupling specificity at a class A GPCR. Sci Adv doi:10.1126/sciadv.adq3971 |
| 2025 | Structural insights into the agonist activity of the nonpeptide modulator JR14a on C3aR. Cell Discov doi:10.1038/s41421-024-00765-x |
| 2025 | Structural basis of oligomerization-modulated activation and autoinhibition of orphan receptor GPR3. Cell Rep doi:10.1016/j.celrep.2025.115478 |
| 2025 | Mechanism and function of GPR3 regulated by a negative allosteric modulator. Nat Commun doi:10.1038/s41467-025-63422-1 |
| 2025 | Systematic metabolite screening identifies functional regulators of the adenosine A2A receptor. Commun Chem doi:10.1038/s42004-025-01825-3 |
| 2025 | Molecular basis of ligand binding and receptor activation at the human A 3 adenosine receptor. Nat Commun doi:10.1038/s41467-025-62872-x |
| 2025 | Extracellular nanobody screening using conformationally stable GPCR variants. Proc.Natl.Acad.Sci.USA doi:10.1073/pnas.2508879122 |
| 2025 | Cryo-EM structure of a cell-free synthesized full-length human beta 1-adrenergic receptor in complex with G s . Structure doi:10.1016/j.str.2025.07.020 |
| 2025 | Structural insights into endogenous agonist selectivity of aminergic receptors from the octopamine beta 2 receptor. Pnas Nexus doi:10.1093/pnasnexus/pgaf376 |
| 2025 | Structural insights into small-molecule agonist recognition and activation of complement receptor C3aR. Embo J. doi:10.1038/s44318-025-00429-w |
| 2025 | Structure-guided engineering of snake toxins for selective modulation of adrenergic and muscarinic receptors. Nat Commun doi:10.1038/s41467-025-61695-0 |
| 2025 | Computational design of highly signalling-active membrane receptors through solvent-mediated allosteric networks. Nat.Chem. doi:10.1038/s41557-024-01719-2 |
| 2024 | Photoswitch dissociation from a G protein-coupled receptor resolved by time-resolved serial crystallography. Nat Commun doi:10.1038/s41467-024-55109-w |
| 2024 | Structural insights into the high basal activity and inverse agonism of the orphan receptor GPR6 implicated in Parkinson's disease. Sci.Signal. doi:10.1126/scisignal.ado8741 |
| 2024 | Structural insight into the dual-antagonistic mechanism of AB928 on adenosine A 2 receptors. Sci China Life Sci doi:10.1007/s11427-023-2459-8 |
| 2024 | Molecular Mechanism of the beta 3 AR Agonist Activity of a beta-Blocker. Chempluschem doi:10.1002/cplu.202400288 |
| 2024 | 7.10 MAG. A Novel Host Monoacylglyceride for In Meso (Lipid Cubic Phase) Crystallization of Membrane Proteins. Cryst.Growth Des. doi:10.1021/acs.cgd.4c00087 |